Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Capital Expenditures (2016 - 2025)

Nutex Health's Capital Expenditures history spans 12 years, with the latest figure at $64000.0 for Q1 2025.

  • For Q1 2025, Capital Expenditures fell 91.27% year-over-year to $64000.0; the TTM value through Mar 2025 reached $4.1 million, down 63.2%, while the annual FY2024 figure was $2.3 million, N/A changed from the prior year.
  • Capital Expenditures for Q1 2025 was $64000.0 at Nutex Health, down from $395349.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $21.7 million in Q2 2021 and bottomed at -$7.9 million in Q4 2022.
  • The 5-year median for Capital Expenditures is $3.5 million (2021), against an average of $4.9 million.
  • The largest YoY upside for Capital Expenditures was 68.72% in 2022 against a maximum downside of 167.23% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $11.7 million in 2021, then tumbled by 167.23% to -$7.9 million in 2022, then soared by 136.49% to $2.9 million in 2023, then crashed by 86.25% to $395349.0 in 2024, then crashed by 83.81% to $64000.0 in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Capital Expenditures are $64000.0 (Q1 2025), $395349.0 (Q4 2024), and $733000.0 (Q1 2024).